South and Central America Drug Modelling Software Market Analysis, Size, and Share by 2027

The South & Central America drug modelling software market is expected to reach US$ 606.80 million by 2027 from US$ 359.46 million in 2019; it is estimated to grow at a CAGR of 7.1% from 2020 to 2027.

Increasing adoption of in-silico modelling tools in drug discovery, and increasing economic burden of drug discovery in the region are the key factors driving the growth of drug modelling software. However, less adoption in emerging countries is the major factor hindering the market growth in South & Central America.

Drug modelling has become an essential tool in the drug design process. Software based drug discovery and development methods are playing key role in the development of novel drugs. Software based methods such as molecular modelling, structure-based drug design, structure-based virtual screening, ligand interaction and molecular dynamics are considered to be powerful tool for investigation of pharmacokinetic and pharmacodynamic properties of drugs. These methods are fast, accurate, and provide valuable insights of experimental findings and mechanisms of action. In addition, appropriate implementation of these techniques may help in reducing cost of drug designing and development.

Traditional drug discovery and development method includes various challenges such as capital-intensive, high failure rates, and time-consuming. It involves experimental screening of existing libraries of molecules followed by many rounds of chemical synthesis. The process of drug development, from the discovery of a lead compound to its commercial launch, is estimated to take around 10–15 years along with the investment of a huge amount of money. Moreover, only a small proportion of leads that are selected for further investigation during the initial stages of research are translated into clinical research studies. Over a period, the complexities of drug discovery have increased owing to the increasing size of biologics. At present, the pharmaceutical industry is under tremendous pressure to cope with rising capital requirements in drug discovery research and avoid losses due to drug failure.

In the last few years, several computational tools have been developed for the identification, selection, and optimization of pharmacological lead candidates. Currently, there are several computational approaches available for the drug discovery process. The predictive power of these tools has been proven to be very advantageous, allowing researchers to bypass the screening of billions of molecules. As a result, computational services, such as quantitative structure-activity relationship (QSAR), modelling, and computer-aided drug design (CADD), have now become an integral part of the pharmaceutical industry. Moreover, pharmaceutical companies that are focused on the development of large molecules are likely to continue outsourcing their respective drug discovery and development operations from drug modelling providers.

The countries in this region are sequencing complete COVID-19 genome. For instance, countries in Central and South America are the most intense COVID-19 transmission zones, driven by complex factors such as crowded urban settings, and concerns are rising about the pandemic's impact on the treatment of noncommunicable diseases, according to World Health Organization (WHO) officials. Furthermore, trials of vaccines including those developed by Johnson & Johnson, Sinovac and AstraZeneca are already underway or due to start shortly in South and Central America, a current hotspot of the pandemic. Thus, continuous research on COVID19 using drug discovery platforms is expected to fuel the growth of the market.

Rest of South & Central America Drug Modelling Software Market, Revenue and Forecast to 2027 (US$ Mn)

SOUTH & CENTRAL AMERICA DRUG MODELLING SOFTWARE MARKET SEGMENTATION

By Product Type

• Database
• Software
• Others

By Application

• Drug Discovery and Development
• Computational Physiological Medicine
• Disease Modeling
• Medical Imaging
• Predictive Analysis of Drug Targets
• Simulation Software
• Cellular Simulation
• Others

By Country

• Brazil
• Argentina
• Rest of South & Central America

Company Profiles

• Crown Bioscience Inc (JSR life science)
• Compugen Ltd.
• Biognos AB
• Dassault Systèmes
• Acellera

South and Central America Drug Modelling Software Report Scope